Fig. 1

Comparative oncology assessment of ADXS31-164 in dogs with appendicular osteosarcoma. ADXS31-164 therapy was initiated within 7 days after the Week 15 recheck if the canine patient was still free of metastatic disease. Complete blood count (CBC), serum chemistry and urinalysis was performed prior to ADXS31-164 administration and at 3 week intervals until Week 23, with an additional CBC assessed 24 h after each ADXS31-164 dose. Additional correlative immune response data was gathered from serum, whole blood and peripheral blood mononuclear cells (PBMCs) prior to and during ADXS31-164 therapy. PE = physical examination, CXR = 3-view thoracic radiography. PD = progressive disease. Sx = surgery